CGeneTech's Class 1 innovative drug CGT-9475 has achieved dual application and approval in China and the US with the help of Medicilon's one-stop preclinical pharmaceutical R&D service platform

ALK inhibitors have significant advantages in clinical application, but the use of ALK inhibitors will inevitably lead to secondary drug resistance and brain metastases.  The ALK inhibitor CGT-9475 under research by CGeneTech aims to overcome drug resistance and solve the problem of central nervous system metastasis, and conduct high-quality and differentiated development.

In preclinical studies, CGT-9475 can simultaneously inhibit ALK and RET in non-small cell lung cancer cell lines, and shows a good blood-brain barrier penetration effect, which will bring new hope to patients with NSCLC brain metastases.  Therefore, CGT-9475 is expected to be used for subsequent treatment after existing ALK inhibitor resistance.

Medicilon One-Stop R&D Platform

All-round Empowerment of New Drug R&D Acceleration

CGT-9475 is an innovative new drug developed by CGeneTech with high quality and differentiation.  Medicilon, which also focuses on innovation, was entrusted by CGeneTech to provide one-stop preclinical comprehensive R&D services for the development of CGT-9475.  Based on the principle of "complementary advantages and collaborative innovation", the two parties carried out all-round in-depth collaboration, and formulated a series of scientific and rigorous experimental protocols for the R&D of the drug.  Medicilon insists on paying equal attention to efficiency and quality.  While meeting technical and regulatory requirements, Medicilon actively coordinate R&D schedules to achieve seamless connection between every R&D stages.  In the end, under the coordination and collaboration of multiple departments of both parties, Medicilon completed a full set of preclinical research services, providing technical support for CGT-9475 to achieve dual-reporting and dual-approval between China and the United States.

The research and development of new drugs is a comprehensive and systematic project, which requires the collaboration of multiple research departments. Medicilon has established a one-stop preclinical research and development service platform, which covers the entire process of preclinical new drug research, including drug discovery, pharmaceutical research and preclinical research.  One-stop R&D platform, strong integration of advantageous resources and collaboration of cross-departmental, give a full play to the synergistic effect of 1+1>2 and accelerate the development of new drugs.  In addition to providing one-stop preclinical new drug R&D services, Medicilon can also customize services according to customer needs and provide specialized services for a certain link of preclinical research and development.